Dr. Frank Borriello, Alloplex Biotherapeutics Inc’s Founder and CEO, will be speaking at CHI’s 11th Annual Immuno-Ongolocy Summit #IOSummit and chairing the Emerging Cell-Based Therapies session at the Seaport Hotel, Boston, M.A. on August 9.
The session starts at 8.55 am and Dr. Borriello’s presentation ‑ entitled ‘SUPLEXA Platform for Reprogramming of Immune Cells for Treatment of Cancer’ ‑ will commence at 9.30 am.
Early clinical results show that SUPLEXA therapeutic cells are safe, have activity in multiple solid tumor types and induced pharmacodynamic changes in patient PBMC.
View the agenda at: https://www.immuno-oncologysummit.com/T-Cell
